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ABSTRACT
Objective To assess the pharmacodynamic effects
of sifalimumab, an investigational anti-IFN-α monoclonal
antibody, in the blood and muscle of adult
dermatomyositis and polymyositis patients by measuring
neutralisation of a type I IFN gene signature (IFNGS)
following drug exposure.
Methods A phase 1b randomised, double-blinded,
placebo controlled, dose-escalation, multicentre clinical
trial was conducted to evaluate sifalimumab in
dermatomyositis or polymyositis patients. Blood and
muscle biopsies were procured before and after
sifalimumab administration. Selected proteins were
measured in patient serum with a multiplex assay, in the
muscle using immunohistochemistry, and transcripts were
proﬁled with microarray and quantitative reverse
transcriptase PCR assays. A 13-gene IFNGS was used to
measure the pharmacological effect of sifalimumab.
Results The IFNGS was suppressed by a median of
53–66% across three time points (days 28, 56 and 98)
in blood (p=0.019) and 47% at day 98 in muscle
specimens post-sifalimumab administration. Both
IFN-inducible transcripts and proteins were prevalently
suppressed following sifalimumab administration.
Patients with 15% or greater improvement from baseline
manual muscle testing scores showed greater
neutralisation of the IFNGS than patients with less than
15% improvement in both blood and muscle. Pathway/
functional analysis of transcripts suppressed by
sifalimumab showed that leucocyte inﬁltration, antigen
presentation and immunoglobulin categories were most
suppressed by sifalimumab and highly correlated with
IFNGS neutralisation in muscle.
Conclusions Sifalimumab suppressed the IFNGS in
blood and muscle tissue in myositis patients, consistent
with this molecule’s mechanism of action with a positive
correlative trend between target neutralisation and clinical
improvement. These observations will require conﬁrmation
in a larger trial powered to evaluate efﬁcacy.
INTRODUCTION
The inﬂammatory myopathies dermatomyositis and
polymyositis are rare autoimmune disorders
affecting skeletal muscle function.1–3 Conventional
treatment options for these diseases include
immunosuppressant drugs associated with a wide
range of side effects. There is a strong unmet
medical need for better therapeutic alternatives.4–6
The role of type I IFN in the pathogenesis of myo-
sitis has been well documented. Immunohistochemical
studies demonstrate that IFN is elevated in muscle
tissue,7 and plasmacytoid dendritic cells (DC) are
present in the muscle and skin of dermatomyositis
patients.8 9 Measuring free IFN-α in the serum is less
sensitive compared to measuring type I IFN-inducible
transcripts, as has been reported in many studies.10–13
These type I IFN-inducible transcripts measured in the
blood of myositis patients correlate with disease activ-
ity in dermatomyositis.14–18 Reports have recently
indicated that the type I IFN signature in the blood of
dermatomyositis patients correlates with IFN-β, not
IFN-α protein expression.19
In a phase 1b clinical trial (MI-CP151) in adult
patients with dermatomyositis or polymyositis
evaluating the safety and tolerability of multiple
intravenous doses of sifalimumab, an investigational
anti-IFN-α monoclonal antibody (MI-CP151), we
report here the clinical utility of the type I IFN
gene signature (IFNGS) as a pharmacodynamic
marker in both blood and muscle of patients
treated with sifalimumab, similar to the approach
used in systemic lupus erythematosus (SLE).10 20–23
Blood and/or muscle tissues from a total of 26
dermatomyositis and 25 polymyositis patients were
transcript proﬁled at baseline (pre-dose) and up to
98 days post initial dose with either placebo or one
of four dose levels for sifalimumab. We also exam-
ined the effects of sifalimumab on pathways down-
stream of type I IFN. Finally, correlative trends
were examined between neutralisation of the
IFNGS and changes in disease activity following
administration of sifalimumab.
METHODS
Myositis patients and controls
MI-CP151 was a phase 1b randomised, double-blind,
placebo controlled, dose-escalation, multicentre
study to evaluate multiple intravenous doses of sifali-
mumab, in adult patients with dermatomyositis or
polymyositis (NCT00533091). Primary trial objec-
tives were to evaluate the safety and tolerability of
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sifalimumab in dermatomyositis or polymyositis patients, while
one of the exploratory objectives included the assessment of the
effects of sifalimumab on pharmacodynamic markers in blood and
disease tissue. A description of the latter objective is the scientiﬁc
focus of this paper. Fifty-one patients were enrolled with seven,
eight, 16 and eight patients dosed with sifalimumab at 0.3, 1, 3
and 10 mg/kg, respectively, and 12 received placebo. Patients
received treatment for 6 months with 14 doses (every other week
dosing), while patients receiving placebo were dosed for 3 months,
then switched to sifalimumab for 3 months with seven doses
beginning at day 98.
Sixty-one different immunosuppressant agents or corticoster-
oids were used among 37 patients, with prednisone (n=30) and
methotrexate (n=15) being the two most common. No correl-
ation was observed between baseline prednisone or methotrex-
ate dose and baseline IFNGS.
MI-CP151 was conducted in accordance with the Declaration
of Helsinki, and the study protocol was approved by the institu-
tional review board at each site. All patients provided written
informed consent before study-related procedures were per-
formed. IFNGS scores in blood were prescreened to stratify
patients. The baseline clinical characteristics and IFNGS status
summaries are provided in table 1.
For the detailed study inclusion and exclusion criteria, IFNGS
calculation, RNA extraction, transcript and protein assays, and
immunohistochemistry see supplementary material (available
online only).
RESULTS
Safety proﬁle of sifalimumab
Before day 98, a total of 49 treatment-emergent adverse event
(TEAE) occurred in 10/12 subjects (83.3%) in the placebo
group and 172 TEAE occurred in 34/39 subjects (87.2%) in the
any sifalimumab group. The most frequent adverse event in
either group was headache. During open-label sifalimimumab
administration on or after day 98, 306 TEAE occurred in 47/51
(92.2%) subjects in all cohorts. Anti-drug antibodies to sifalimu-
mab were detected in less than one-ﬁfth of the subjects across
the sifalimumab dose groups. Anti-drug antibody titres did not
have an obvious impact on sifalimumab pharmacokinetics. The
combination of the safety database size and trial design limits
the interpretation of the safety proﬁle of this molecule;
however, a larger study (N=161) that characterises the safety
proﬁle of sifalimumab in SLE has recently been accepted.24
No deaths occurred in this study (see supplementary material,
available online only, for a detailed safety summary).
Target modulation of an IFNGS by sifalimumab in the blood
and muscle of myositis patients
Dermatomyositis (n=26) or polymyositis (n=25) patients enrolled
in this study were screened using their baseline 13 IFNGS
described previously15 (detailed in supplementary material, avail-
able online only), then randomly assigned to either placebo or sifa-
limumab groups. Of the 51 patients enrolled, 75% (38/51) had a
positive baseline IFNGS (table 1 and see supplementary ﬁgure S1,
available online only). A previous study showed that approxi-
mately 60% of dermatomyositis or polymyositis patients demon-
strate an elevated IFNGS in the blood.15 The baseline IFNGS in
dermatomyositis or polymyositis patients calculated using microar-
rays were conﬁrmed by taqMan quantitative reverse transcriptase
PCR (r=0.95; p<0.001; see supplementary ﬁgure S2, available
online only).
The same 13 type I IFN-inducible genes were also used to evalu-
ate the pharmacodynamics of sifalimumab on target neutralisation
in IFNGS-positive patients. The total numbers of dermatomyositis
or polymyositis patients who had specimens available for correla-
tive studies at baseline were 26 and 21 for blood, and 23 and 25
for muscle, respectively (see supplementary material, available
online only, for patient counts at each time point).
In blood, target neutralisation was observed in sifalimumab-
dosed patients in three dose groups relative to placebo-dosed
patients after the ﬁrst dose and sustained to day 98 (ﬁgure 1A,B).
After day 98, placebo-dosed patients crossed over and received
sifalimumab. Graphs displaying target neutralisation up to day
196 post initial dosing are provided in supplementary ﬁgure S3
(available online only). The IFNGS in the blood is maximally
neutralised in the 0.3 mg/kg cohort (91% at day 98; p=0.002
at all time points). At day 98, the IFNGS is neutralised from
54% to 91% in 0.3, 1.0 and 3.0 mg/kg cohorts (p=0.002, 0.05
and 0.014, respectively). The 10 mg/kg cohort did not show a
signiﬁcant difference from placebo at day 98 (p=0.28),
although this cohort had the smallest sample size (n10mg/kg=4 vs
nplacebo=4). As expected, the placebo-dosed patients showed no
target neutralisation across all times points. The median of all
four dose cohorts combined show that the IFNGS is neutralised
from 53% to 66% across the three time points, compared to the
placebo (ﬁgure 1B; Hotelling’s T2 p=0.019). Dose-dependent
target neutralisation was not observed in the blood.
All four sifalimumab cohorts show dose-dependent target
neutralisation in muscle that differs from the placebo cohort
(ﬁgure 1C) with a median for combined sifalimumab cohorts of
47% target neutralisation (ﬁgure 1D), although the difference
was not statistically signiﬁcant. The medians do, however, show
a trend towards a difference from placebo, noting that the
sample sizes for the muscle specimens were generally lower than
those available from the blood.
The neutralisation of the IFNGS was represented in a heat
map for each patient at days 28, 56 and 98 post-administration
in blood and day 98 in muscle specimens with either sifalimu-
mab or placebo (ﬁgure 2). The majority of sifalimumab-dosed
patients exhibit strong, sustained and durable target neutralisa-
tion in blood and muscle, while the majority of the placebo-
dosed patients do not. Of sifalimumab-dosed patients showing
greater than 20% target neutralisation at day 98 in muscle,
75%, 55% and 72% of patients at days 28, 56, and 98, respect-
ively are concordant in the blood.
The IFN-α protein was not measurable in all but a few
patients in the blood with luciferase reporter assay.
Transcripts and proteins most neutralised in the blood
and serum by sifalimumab
The speciﬁcity of the transcripts most neutralised by sifalimu-
mab administration was evaluated on a patient-by-patient level,
using at least 50% neutralisation in the blood for each patient
visit. Transcripts neutralised in over 25% of sifalimumab-dosed
patients were ranked across all post-dose time points up to day
98. The top 200 transcripts most neutralised by this criterion
are provided in supplementary table S1 (available online only).
Among them, 48% are type I IFN inducible, including all 13
genes in the pharmacodynamic biomarker for this
trial.14 20 21 25 A similar observation was reported in a sifalimu-
mab trial in SLE.10 23 Among measured serum proteins, ﬁve of
11 that were signiﬁcantly suppressed by sifalimumab (false dis-
covery rate (FDR) p<0.05) are IFN inducible (sIL2R, MCP1,
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MCP2, BAFF and Ferritin). Immunohistochemistry analysis was
also performed on a small subset of paired patient muscle tissue
to assess general signs of inﬂammation using BDCA2, a marker
for plasmacytoid DC; CD83, a marker for myeloid DC; and
IP-10, an IFN-inducible protein. A representative polymyositis
patient showing decreases in BDCA2, CD83 and IP-10 98 days
post-dosing with sifalimumab is shown in supplementary ﬁgure
S4 (available online only), although with the heterogeneity of
the specimens and small patient subset, no signiﬁcant conclusion
can be drawn.
Target neutralisation correlates with MMT8 improvement
in IFNGS-positive myositis patients
To evaluate any trend between neutralisation of the IFNGS by
sifalimumab and improvement in disease activity, we evaluated
the proportion of signature-positive patients dosed with sifali-
mumab with neutralisation at day 98 (the last dose before
placebo crossing over) relative to pretreatment in 5% incre-
ments. Patients were classiﬁed into two groups: showing 15% or
greater improvement in Manual Muscle Testing (MMT8) (US
Food and Drug Administration accepted clinical endpoint for
Figure 1 Median target neutralisation (with median absolute deviation error bars) of the IFN gene signature (IFNGS) as calculated based on the
expression of 13 genes (see supplementary material, available online only) pre-dose and post-dose up to day 98 for dose cohorts of 0.3 mg/kg
(green), 1 mg/kg (blue), 3 mg/kg (orange), 10 mg/kg (purple) and placebo (red) in (A) blood and (C) muscle specimens, as well as median combined
dose cohorts (blue) versus placebo treatment cohorts (red) in (B) blood and (D) muscle specimens from dermatomyositis or polymyositis patients.
The y-axis represents the percentage of IFNGS remaining following treatment; each line is the median of the respective dose cohort. p Values at
each time point for each dose cohort are provided in supplementary material (available online only), while those with p<0.05 are marked with an
asterisk.
Table 1 MI-CP151 patient summary information
Sifalimumab (all
doses, N=39)
Sifalimumab
(0.3 mpk, N=7)
Sifalimumab
(1.0 mpk, N=8)
Sifalimumab
(3.0 mpk, N=16)
Sifalimumab
(10 mpk, N=8)
Placebo
(N=12)
Age, years 51.3 (20–77) 47.3 (29–59) 52.4 (20–77) 51.8 (21–76) 52.8 (37–67) 51 (33–67)
% Female 74 (29/39) 88 (4/7) 88 (7/8) 69 (11/16) 88 (7/8) 58 (7/12)
% Caucasian 79 (31/39) 100 (7/7) 63 (5/8) 82 (13/16) 75 (6/8) 67 (8/12)
% Hispanic 15 (6/39) 14 (1/7) 13 (1/8) 25 (4/16) 0 (0/8) 17 (2/12)
% Dermatomyositis 54 (21/39) 29 (2/7) 38 (3/8) 81 (13/16) 38 (3/8) 42 (5/12)
Viral reactivation history 6 (15.4%) 1 (14.3%) 2 (25.0%) 2 (12.5%) 1 (12.5%) 2 (16.7%)
Mean baseline MMT8
(max=150)
117.7 123.6 113.8 112.9* 125.9 119.8
% Corticosteroid use at
baseline
84.6 85.7 87.5 100 50 66.7
Disease duration, months,
median (range)
40.3 (3–361.5) 31.5 (3–153.9) 23.6 (15.3–361.5) 53.1* (13.8–217.2) 35.4 (4.3–109.9) 36.9 (10.8–76.9)
% Signature positive 72 (28/39) 86 (6/7) 100 (8/8) 63 (10/16) 50 (4/8) 83 (10/12)
*Indicates average from cohorts 3 mpk IFN gene signature (IFNGS) positive (N=7) and 3 mpk IFNGS negative (N=9).
See supplementary material (available online only) for IFNGS-positive blood and muscle patient counts at each time point. IFNGS-positive patient counts above are provided for those
with available microarray data at day 0 in either blood or muscle specimens, or both. Only these IFNGS-positive patients are used in the analyses presented.
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efﬁcacy in dermatomyositis and polymyositis) at day 98 com-
pared to predose or showing less than 15%. Figure 3 shows the
results in both blood and muscle specimens from 14 dermato-
myositis and 10 polymyositis patients. In the blood sifalimumab
dose group (ﬁgure 3A), there is a clear separation between the
15% or greater MMT8 improvers and the less than 15%
MMT8 improvers at each IFNGS neutralisation threshold value
after 20%—the largest gap existing between 45% and 100%.
This indicates that for the 15% and greater MMT8 improvers
at day 98, a larger proportion (y-axis) showed greater
Figure 2 Target neutralisation of the
IFN gene signature (IFNGS) calculated
at days 28 (n=36), 56 (n=31) and 98
(n=32) post-treatment in blood
specimens (ﬁrst three columns) and
day 98 (n=30) post-treatment in
muscle specimens (last column) with
either sifalimumab (blue vertical bar)
or placebo (green vertical bar) on a
patient level (designated on the right
y-axis). Each row indicates a patient
with values approaching red,
representing maximum neutralisation
of the IFNGS and values approaching
blue, representing minimum
neutralisation. Both blood and muscle
comparisons are made to day 0
(pre-treatment) and all columns are
sorted based on the day 28 column
values. Neutralisation values in black
indicate missing data points.
Figure 3 Stratiﬁed target
neutralisation curves representing the
proportion of dermatomyositis (n=14)
or polymyositis (n=10) patients dosed
with sifalimumab who demonstrate
neutralisation of their IFN gene
signature (IFNGS) at day 98 at the
provided threshold value on the x-axis
in (A) blood and (B) muscle specimens.
Plots include all IFNGS-positive
patients. Patients who exhibited a
15% or greater improvement in MMT8
score at day 98 (compared to day 0)
are represented by the blue lines
(blood n=8; muscle n=7), while those
patients who did not are represented
by the purple lines (blood n=16;
muscle n=17).
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neutralisation of the IFNGS, compared to the less than 15%
MMT8 improvers. A few patients dosed with placebo also
showed MMT8 improvement of 15% or greater at day 98,
although no appreciable modulation of the IFNGS was observed
in these patients and they did not demonstrate a substantial
target modulation difference between 15% or greater MMT8
improvers and less than 15% MMT8 improvers.
For the muscle biopsy specimens (ﬁgure 3B), a similar trend
exists, although not as pronounced as in blood, with a slightly
higher intersection between the curves at the IFNGS neutralisation
threshold less than 40%. The placebo-dosed muscle specimens
have a more deﬁned difference in IFNGS neutralisation between
15% and greater MMT8 improvers and less than 15% MMT8
improvers, although it is restricted to between 20% and 40%
target modulation thresholds. Overall, sample sizes for the
placebo-dosed specimens are much smaller than sifalimumab-
dosed specimens, so trends should be interpreted with caution
until conﬁrmed in a larger trial. Similar analysis for dermatomyo-
sitis or polymyositis patients alone are not shown, as the results are
unlikely to be meaningful due to the small sample size. One repre-
sentative patient with an improvement of the MMT8 score of
15% or greater at day 98 after sifalimumab administration is
shown in supplementary ﬁgure S5 (available online only).
Sifalimumab suppressed pathways downstream of type I IFN
in muscle from myositis patients
Pathways besides type I IFN that were signiﬁcantly affected follow-
ing administration of sifalimumab in muscle specimens from derm-
atomyositis or polymyositis patients were evaluated. Transcripts
suppressed by at least 37.5% in at least ﬁve sifalimumab-dosed
patients and displaying an odds ratio (calculated as patients with
target neutralisation >37.5% or <37.5% for each transcript)
greater than 2 relative to placebo-dosed patients were retained for
pathway enrichment analysis. In all, 86 pathways were suppressed
by sifalimumab. Among the top enriched pathways were antigen
presentation (11 transcripts; B–H p=0.003), leucocyte extravasa-
tion signalling (33 transcripts; B–H p=0.0009) and B-cell develop-
ment (10 transcripts; B–H p=0.004) (ﬁgure 4A–C; see
supplementary ﬁgure S6A–C, available online only).
To conﬁrm these results, we compared these pathways sup-
pressed by sifalimumab to four primary gene signatures that were
elevated in muscle biopsies in a previous study evaluating 31 derm-
atomyositis or polymyositis patients26 (see supplementary
material, available online only). Brieﬂy, a leucocyte index, a MHC
class I signature, an immunoglobulin signature and an IFNGS
were able to characterise and quantify the inﬂammatory cell inﬁl-
tration in the muscle of myositis patients at the molecular level.
The leucocyte signature was correlated with the three other signa-
tures and was concordant with H&E staining results from the
same patient biopsies in that study. We evaluated the effects of
sifalimumab on these signatures in muscle. The neutralisation of
the leucocyte index was signiﬁcantly correlated with the neutralisa-
tion of the IFNGS in muscle (Spearman test r=−0.93, p<0.001;
ﬁgure 5A), as was the signatures of MHC class I and immuno-
globulin (Spearman test r=−0.84, p<0.001 and r=−0.64,
p=0.001, respectively; ﬁgure 5B,C).
DISCUSSION
In this phase 1b trial evaluating sifalimumab in myositis, we
showed that a 13-gene IFNGS can monitor the level of type I
IFN activity in both the peripheral blood and muscle of dermato-
myositis or polymyositis patients, similar to that observed in a
sifalimumab trial in SLE10 (see supplementary ﬁgure S1, available
online only). Sifalimumab shows strong neutralisation of the
IFNGS in blood up to day 98 at three dose levels and is distinct
from the placebo-dosed cohort, although the 10 mpk cohort in
blood does not reﬂect this difference (ﬁgures 1 and 2). The acti-
vation of the type I IFN pathway is concordant in blood and
muscle, supporting a pharmacodynamic marker to evaluate the
mechanism of action of sifalimumab. Although the safety data-
base is small, the adverse events were of low severity and serious
adverse events were uncommon.
Type I IFN-inducible transcripts make up 48% of those most
neutralised in blood (see supplementary table S1, available
online only), and ﬁve of 11 proteins signiﬁcantly suppressed are
IFN inducible in serum, demonstrating the speciﬁcity of sifali-
mumab to suppress the type I IFN pathway in myositis.
There is no clear dose-dependent target neutralisation in
blood, as opposed to the trend observed in the muscle (albeit
not statistically signiﬁcant). The small sample size accompanied
by patient-to-patient variability could contribute to this observa-
tion. Furthermore, neutralisation by sifalimumab may be partly
bypassed via IFN-β or other type I IFN family members besides
IFN-α. Sifalimumab binds to the majority of the IFN-α subtypes
with high afﬁnities, but not to other type I IFN. The prevalence
of IFN-β compared to IFN-α, and its contribution to the disease
Figure 4 Three of the pathways most suppressed by sifalimumab at day 98 in muscle specimens from dermatomyositis or polymyositis patients
and unique to type I IFN signalling. Each point indicates a gene in either the (A) leucocyte extravasation pathway, (B) antigen presentation pathway,
or (C) B-cell development pathway treated with either sifalimumab (blue squares) or placebo (red triangles). The y-axis represents the percentage of
patients with at least 37.5% neutralisation of pathway-enricheds transcripts at day 98 in muscle tissue specimens.
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pathogenesis in myositis, is less clear. The IFN-β level in the
blood has been shown to be both unique to and correlate with
an elevated IFNGS in dermatomyositis.19 Cappelletti et al27
showed that IFN-β and not IFN-α transcripts were overex-
pressed in polymyositis as well as dermatomyositis and juvenile
dermatomyositis muscle, suggesting a local source of IFN-β that
might contribute to the lack of stronger target neutralisation by
sifalimumab in muscle compared to blood beyond the variation
in pharmacokinetic proﬁle in individual patients. Furthermore,
type III IFN signalling can similarly bypass effects of sifalimu-
mab and induce activation of IRF-9 and transcription of
IFN-inducible genes,28 although IFN-λ induces a much smaller
effect on IFNGS in blood (data not shown). Stimulation of puri-
ﬁed human plasmacytoid DC with virus or Toll-like receptor 9
agonist, CpG A showed that one subset of cells produced IFN-α
only, while another subset produced IFN-α and IFN-λ.29 A
larger study, particularly one comparing sifalimumab to an anti-
type I IFN receptor (IFNAR) monoclonal antibody, will help to
explain if blockage of the type I IFN pathway would clinically
beneﬁt myositis patients, and what type I IFN contributes to the
pathogenesis and drives the disease progression.
In a previous independent study of dermatomyositis or poly-
myositis patients, a leucocyte index, an MHC class I signature and
an immunoglobulin signature were overexpressed in muscle biop-
sies and positively correlated with the IFNGS.26 Independent
pathway analysis conducted across the transcriptome in this study
identiﬁed three similar pathways—leucocyte extravasation, antigen
presentation and B-cell development (ﬁgure 5A–C, respectively),
which were preferentially suppressed in muscle biopsies following
exposure to sifalimumab. The leucocyte index and immunoglobu-
lin signature represented the level of leucocyte inﬁltration and
abundance of plasma cells in the myositis muscle, respectively.
Type I IFN plays a critical role in the self-sustaining inﬂammatory
response, contributing to leucocyte inﬁltration as well as the upre-
gulation of MHC class I expression on the cell surface of muscle
ﬁbres.30 For both dermatomyositis and polymyositis, the inﬂam-
matory cell inﬁltrates are primarily composed of CD4 cells, DC
and macrophages, whereas polymyositis has an additional CD8
T-cell component.31 32 In addition, DC inﬁltrates may act as both
antigen presenting cells and as a major source of type I IFN in the
diseased tissue,33 and contribute directly to disease pathogenesis
and sustained inﬂammation at the disease site. In this study, all
three inﬂammation-related signatures were suppressed concor-
dantly with the modulation of the IFNGS in muscle following
administration of sifalimumab (ﬁgure 5), consistent with the bio-
logical function of IFN-α.
Modulation of the type I IFN signature in both blood and
muscle of dermatomyositis or polymyositis patients dosed with
sifalimumab positively correlates with MMT8 improvement at
day 98. It should be noted that a few patients receiving placebo
also showed clinical improvement at day 98 based on MMT8
with no target neutralisation in either blood or muscle. One
likely explanation is that some patients respond favourably to
standard of care (ie, immunosuppressive medications). As
MI-CP151 was not designed to evaluate the clinical efﬁcacy of
sifalimumab, the true clinical beneﬁt of sifalimumab (on top of
standard of care) in myositis needs to be evaluated in a carefully
designed trial with sufﬁcient statistical power.
This study shows the utility of an IFNGS as a pharmacody-
namic biomarker for sifalimumab in adult dermatomyositis or
polymyositis patients. Although this clinical trial is modest sized,
we observed substantial target neutralisation of this biomarker
following administration of sifalimumab in blood with a trend
in muscle tissue, as well as suppressed signalling activity in
several important inﬂammatory pathways. Preliminary results
indicate a positive trend between target neutralisation of the
IFNGS and reduction in disease activity in dermatomyositis or
polymyositis patients, an observation that needs additional con-
ﬁrmation. This potential association between the mechanism of
action of sifalimumab and clinical beneﬁt, coupled with the lack
of complete target neutralisation by sifalimumab, raises the pos-
sibility that blockage of the IFNAR might show superior clinical
beneﬁt in myositis patients. This hypothesis, along with a better
understanding of the potential contribution of other IFN types,
needs to be rigorously evaluated in future clinical trials.
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